JNCI Cancer Spectrum

JNCI Cancer Spectrum is a peer-reviewed, fully open access online journal founded in 2017 and published by Oxford University Press as a sister journal to the Journal of the National Cancer Institute, publishing across the full spectrum of clinical and translational cancer research, with a 2025 Journal Impact Factor of 4.8.《JNCI 癌症谱》（JNCI Cancer Spectrum）是（Oxford University Press）于 2017 年创办的同行评审完全开放获取在线期刊，为（Journal of the National Cancer Institute）的姊妹刊，发表涵盖临床与转化癌症研究全谱系的成果，2025 年影响因子为 4.8。

Scope

• The journal publishes manuscripts that describe new findings of particular significance across a full range of clinical and translational cancer research, including prevention, screening and treatment.该刊发表具有特别意义的临床与转化癌症研究新发现，涵盖预防、筛查与治疗全范围。
• Clinically relevant epidemiologic, public health and policy research is a core strand of its content.具有临床意义的流行病学、公共卫生与政策研究是其核心内容之一。
• Besides novel results, the journal considers studies with meaningful confirmatory or negative findings, and it encourages systematic reviews, meta-analyses and expert reviews of important topics.除新颖结果外，该刊亦考虑具有实质意义的验证性或阴性结果研究，并鼓励对重要主题的系统综述、荟萃分析与专家述评。
• It invites scholarly manuscripts discussing emerging hypotheses and research priorities, as well as commentaries on important cancer-related issues.该刊邀请探讨新兴假设与研究优先事项的学术稿件，以及针对重要癌症议题的评论。
• Its remit runs from population health and epidemiology to prospective and retrospective clinical research and translational work, spanning health services and policy as well as psychosocial and palliative care research.其收稿范围从人群健康与流行病学到前瞻性与回顾性临床研究及转化工作，兼及卫生服务与政策以及心理社会与姑息治疗研究。
• The journal employs a rigorous yet rapid review process, and high-quality manuscripts transferred from its sister journal undergo expedited review reusing the reviews already obtained there.该刊实行严谨而快速的评审流程，自姊妹刊转来的高质量稿件可沿用已完成的评审意见加速审理。

History

• The journal was launched in 2017 by Oxford University Press as a sister title to the Journal of the National Cancer Institute, and its first issue appeared in September 2017.该刊由（Oxford University Press）于 2017 年创办，作为（Journal of the National Cancer Institute）的姊妹刊，首期于 2017 年 9 月出版。
• The publisher states explicitly that the journal is not affiliated with the United States National Cancer Institute, despite the shared JNCI family branding.尽管同属 JNCI 品牌家族，出版方明确声明该刊与美国国家癌症研究所无从属关系。
• Pamela J. Goodwin of Mount Sinai Hospital in Toronto served as the inaugural Editor-in-Chief until the end of 2020, when Ronald C. Chen took over, and James B. Yu has led the journal since 2024.多伦多西奈山医院（Mount Sinai Hospital）的 Pamela J. Goodwin 任创刊主编至 2020 年底，其后由 Ronald C. Chen 接任，2024 年起由 James B. Yu 执掌。^[1][2]
• The journal gained Scopus and PubMed Central indexing in 2020 and was selected for the Emerging Sources Citation Index, entering the Web of Science Core Collection.该刊于 2020 年获（Scopus）与（PubMed Central）收录，并入选新兴来源引文索引，进入（Web of Science）核心合集。
• The 2025 Journal Impact Factor is 4.8, against 4.1 in 2024, with a five-year impact factor of 4.5 and a CiteScore of 6.0, and Journal Citation Reports places the journal in Q2 of Oncology, ranked 92nd of 333 titles.2025 年影响因子为 4.8，2024 年为 4.1，五年影响因子 4.5，（CiteScore）为 6.0，期刊引用报告将其列人肿瘤学类 Q2 区，在 333 种期刊中排名第 92。
• It is a gold open access journal charging an article processing charge of up to USD 1951 with a waiver policy, under CC BY, CC BY-NC or CC BY-NC-ND licences, and it launched an annual Early Career Investigator Research Collection in 2026.该刊为金色开放获取期刊，文章处理费最高 1951 美元并设减免政策，许可为（CC BY）、（CC BY-NC）或（CC BY-NC-ND），并于 2026 年推出年度早期职业研究者（Early Career Investigator）研究专辑。

Editors

• The Editor-in-Chief is James B. Yu, Professor of Radiation Oncology at Dartmouth Hitchcock Medical Center and the Geisel School of Medicine at Dartmouth, whose research centres on the comparative effectiveness and national adoption of new radiation technologies.主编 James B. Yu 为达特茅斯希契科克医疗中心（Dartmouth Hitchcock Medical Center）与达特茅斯盖泽尔医学院的放射肿瘤学教授，研究聚焦新放疗技术的比较效果与全国推广采用。
• He co-edited the textbook Principles of Clinical Cancer Research, authored more than 300 peer-reviewed manuscripts, and took up the post in 2024 after serving as an associate editor and deputy editor of the journal.他联合主编教材（Principles of Clinical Cancer Research），发表 300 余篇同行评审论文，在历任该刊副编辑与副主编后于 2024 年就任主编。
• The deputy editors are Matthew F. Hudson, Director of Cancer Care Delivery Research at Prisma Health and Professor of Medicine at the University of South Carolina School of Medicine Greenville, and Martin Stockler, Professor of Oncology and Clinical Epidemiology at the NHMRC Clinical Trials Centre, University of Sydney.副主编为（Prisma Health）癌症照护服务研究主任、南卡罗来纳大学格林维尔医学院医学教授 Matthew F. Hudson，以及悉尼大学（NHMRC）临床试验中心肿瘤学与临床流行病学教授 Martin Stockler。
• Yago Garitaonaindia of Herlev Hospital in Denmark serves as Social Media Editor, and the associate editors include Sanjay Aneja of Yale School of Medicine, Jorge Barriuso of Hospital Universitario 12 de Octubre in Spain, Gagan Prakash of the Tata Memorial Centre in India, and Haryana Dhillon and Melissa Southey in Australia.丹麦海勒弗医院（Herlev Hospital）的 Yago Garitaonaindia 任社交媒体编辑，副编辑包括耶鲁大学医学院的 Sanjay Aneja、西班牙十月十二日大学医院（Hospital Universitario 12 de Octubre）的 Jorge Barriuso、印度塔塔纪念中心（Tata Memorial Centre）的 Gagan Prakash，以及澳大利亚的 Haryana Dhillon 与 Melissa Southey。
• A statistical editorial board supports methodological rigour, with members such as Ana Best of the National Cancer Institute and Qian Shi of the Mayo Clinic, while the wider editorial board includes researchers such as Lisa Gallicchio of the National Cancer Institute.统计编辑委员会为方法学严谨性提供支撑，成员包括美国国家癌症研究所的 Ana Best 与梅奥诊所的 Qian Shi，更广泛的编委会则包括美国国家癌症研究所的 Lisa Gallicchio 等研究者。
• Peer review is single anonymous, the journal shares editorial staff with the Journal of the National Cancer Institute, and it reports a median of 13.5 days from acceptance to publication.该刊实行单盲同行评审，与（Journal of the National Cancer Institute）共享编辑团队，并公布录用至出版的中位时间为 13.5 天。